Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) EPS (Basic) (2016 - 2025)

Acro Biomedical (ACBM) has 8 years of EPS (Basic) data on record, last reported at -$0.05 in Q2 2023.

  • For Q2 2023, EPS (Basic) rose 20.05% year-over-year to -$0.05; the TTM value through Jun 2023 reached -$0.05, up 20.05%, while the annual FY2021 figure was -$0.14, 5592.83% down from the prior year.
  • EPS (Basic) reached -$0.05 in Q2 2023 per ACBM's latest filing, up from -$0.07 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.0 in Q1 2020 and bottomed at -$0.07 in Q4 2021.
  • Average EPS (Basic) over 5 years is -$0.03, with a median of -$0.01 recorded in 2019.
  • Peak YoY movement for EPS (Basic): surged 147.79% in 2020, then plummeted 5312.25% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.0 in 2019, then grew by 18.59% to -$0.0 in 2020, then plummeted by 5312.25% to -$0.07 in 2021, then grew by 4.56% to -$0.07 in 2022, then grew by 20.34% to -$0.05 in 2023.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.05 in Q2 2023, -$0.07 in Q1 2023, and -$0.07 in Q3 2022.